## **SUPPLEMENTAL MATERIAL**

## **The Phosphoenolpyruvate:Sugar Phosphotransferase system is involved in sensitivity to the glucosylated bacteriocin sublancin**

C. V. Garcia De Gonzalo<sup>1\*</sup>, E. L. Denham<sup>2,3\*</sup>, R. A. T. Mars<sup>3a</sup>, J. Stülke<sup>4</sup>, W. A. van der Donk<sup>1</sup>, and I. M. van Dijl<sup>3</sup>

\*Equal contribution 

1 - Howard Hughes Medical Institute and Roger Adams Laboratory, Department of Chemistry, University of Illinois at Urbana–Champaign, 600 South Mathews Avenue, Urbana, Illinois 61801, United States

2 - Division of Translational and Systems Medicine, Unit of Microbiology and Infection, Warwick Medical School, University of Warwick, Coventry, CV4 7AL, UK

3 - Department of Medical Microbiology, University Medical Center Groningen and University of Groningen, Hanzeplein 1, 9700 RB Groningen, the Netherlands a - Current Address

Institute of Molecular Systems Biology, ETH Zürich, Auguste-Piccard-Hof 1, 8093 Zürich, Switzerland 

4 - Institut für Mikrobiologie und Genetik, Abteilung für Allgemeine Mikrobiologie, Grisebachstr. 8, 37077 Göttingen, Germany 



**Supplementary figure S1.** Determination of the specific activity of sublancin against *Bacillus* subtilis ATCC 6633 (left) and *Bacillus halodurans* C-125 (right) by the broth dilution method. Shown are the means of a single experiment conducted in triplicate as a representative of three independent experiments. For both graphs  $R^2 > 0.99$ . Error bars indicate standard deviations.



**Supplementary figure S2. Sublancin does not affect the integrity of the bacterial membrane.** (a) Growth curve of the *B. subtilis* Δ*SPβ* strain in the presence of different concentrations of sublancin. Sublancin was added at O.D.<sub>600nm</sub> 0.5 (vertical grey line). Measurements were performed in a Synergy 4 plate reader every 10 min in triplicate and the means of the growth curve was plotted. (b) LIVE/DEAD® *Bac*Light™ bacterial cell viability assay of the  $\Delta SP\beta$  strain 30 (top) and 90 (bottom) min after exposure to sublancin.

Grey bars depict bacteria with an intact membrane and white bars depict bacteria with a compromised membrane, error bars depict standard deviation of triplicate experiments. A: 100 nM sublancin, B: 200 nM sublancin, C: 300 nM sublancin, D: 400 nM sublancin, E 500 nM sublancin, F Nisin (10 nM) was used as a positive control that does affect the integrity of the membrane, G negative control, no addition of an antimicrobial agent.



**Supplementary figure S3.** Predicted secondary structures of the terminator of (top) wild-type *B. halodurans* C-125 (accession no. NC<sub>-</sub>002570.2) and (bottom) the sublancin resistant mutant *ptsG* leader mRNA. Inset shows a schematic representation of the genomic locus. Terminators are shown in the antisense strand since flanking genes translate in an antisense fashion. The terminator starts at position 920136 and ends at position 920046. The ptsG starts at position 919994. Single nucleotide polymorphisms (SNPs) are labelled in red, and the location in the genome is shown. The RNAstructure Web Server (http://rna.urmc.rochester.edu/RNAstructure Web/index.html) at the University of Rochester Medical Center and the RNAfold Web Server (http://rna.tbi.univie.ac.at/) at

the University of Vienna were used to predict the secondary structures using default parameters. All three mutations result in Watson-Crick base-paired bases that increase the strength of the terminator. The predicted free energy values for the terminator loops were calculated using the RNAstructure Web Server.



**Supplementary figure S4.** *B. subtilis* ∆SPB was spread over M9 agar plates containing 0.3% glucose, 0.4% citrate or 0.4% malate. Sublancin (2  $\mu$ L of 100 nM) was spotted on the plates. The presence of glucose in the media resulted in resistance to sublancin.



**Supplementary table S1.** Oligonucleotides used in this study to generate deletion mutants described in Table 2. Capital letters indicate overlapping regions with phleomycin resistance cassette, lower case letters indicate regions complementary to *B. subtilis* genome. 



**Supplementary table S2.** SNPs in genes of sublancin-resistant *B. halodurans* C-125 mutants determined by Illumina sequencing. The mutation in BH0844 results in a stop codon instead of a Tyr codon at position 160. The predicted domain organization of PtsG of *B. halodurans* C-125 is: 1-424 domain IIC, 425-524 domain IIB, and 525-675 domain IIA (see schematic drawing of the predicted domain organization in Supplementary table S4). Hence, the stop codon would delete most of PtsG and the respective truncated product would likely not be expressed as a stable protein. The mutation in BH3851 results in a His to Arg mutation. As shown in Supplementary figure 3, the mutations in the intergenic region result in a change in the predicted antiterminator structure that may affect transcription of *ptsG.* 





**Supplementary table S3.** Changes in transcript levels in *B. halodurans* C-125 in response to the addition of sublancin. Positive numbers indicate up-regulated transcripts, negative numbers indicate down-regulated transcripts.



**Supplementary table S4.** Predicted topology of PtsG from *B. halodurans* C-125 (BH0844). The multidomain PtsG is 675 amino acids in length. PtsG IIC (region 1-424) is a transmembrane domain. PtsG IIB (region 425-524) and PtsG IIA (region 525-675) are cytoplasmic domains. Prediction obtained from the CAMPS (Computational Analysis of the Membrane Protein Space) database (identifiers: Q9KEK8\_BACHD, GI:15613407).

